Identification of a Novel Metastasis-Related miRNAs-Based Signature for Predicting the Prognosis of Hepatocellular Carcinoma

Yuan Chen,1 Guifu Wang,2 Hao Xu,1 Hao Wang,1 and Dousheng Bai3

1Yangzhou University Medical College, Yangzhou, Jiangsu, China
2Dalian Medical University, Dalian, Liaoning, China
3Department of Hepatobiliary and Pancreatic Surgery, Yangzhou University Clinical Medical College, Yangzhou, Jiangsu, China

Correspondence should be addressed to Dousheng Bai; drbaidousheng@163.com

Yuan Chen and Guifu Wang contributed equally to this work.

Received 4 November 2020; Revised 18 January 2021; Accepted 20 January 2021; Published 1 February 2021

Academic Editor: Raffaele Palmirotta

Copyright © 2021 Yuan Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Hepatocellular carcinoma (HCC) is one of the most common internal malignancies worldwide and is associated with a poor prognosis. Abnormal expression of miRNAs is believed to play a role in the recurrent metastasis of HCC. However, limited studies on the role of miRNAs in HCC metastasis have been carried out. Therefore, this study is aimed at exploring the potential value of metastasis-related miRNAs (MRMs) in HCC. We retrieved MRMs were from the Human Cancer Metastasis Database. Differential miRNAs were identified for tumor samples of HCC patients and normal samples based on the TCGA database. Further, univariate and multivariate Cox regression analyses were used to screen MRMs known to be independent prognostic factors in HCC. These MRMs were then used to build a prognostic signature. All patients were classified into high-risk and low-risk groups based on the median of the signature scores. Moreover, GO and KEGG pathway enrichment analyses were performed to predict the function of these MRMs. Finally, a nomogram was constructed to predict the OS of patients at 1, 2, and 3 years. In our study, a total of seven prognostic MRMs (miR-140-3p, miR-9-5p, miR-942-5p, miR-324-3p, miR-29c-5p, miR-551a, and miR-149-5p) were identified and used for constructing the prognostic signature based on the training cohort. Patients in the low-risk HCC group showed better overall survival (OS) than those in the high-risk group. These results were validated using the validation cohort. In summary, the findings of this study provide evidence that MRMs-based prognostic signature is an independent biomarker in the prognosis of HCC patients.

1. Introduction

Hepatocellular carcinoma (HCC) is the fifth most common malignancy in the world and the second leading cause of cancer-related deaths [1]. Despite significant advances in surgery, liver transplantation, and interventional therapy, the mortality rate remains high as a result of the poor prognosis of HCC patients due to late diagnosis [2]. Tumor metastasis plays a major role in the poor prognosis of HCC patients. Although HCC has many staging systems, such as the American Joint Committee on Cancer (AJCC) TNM stage and the Barcelona-Clinic Liver Cancer (BCLC) system, approaches for evaluation of survival and prognosis of patients are limited [3]. Therefore, there is a need to develop a novel metastasis-related signature for improved prediction of prognosis of HCC patients.

MiRNAs are a class of small endogenous single-stranded noncoding RNAs. MiRNAs downregulate gene expression through targeted degradation of miRNAs or by inhibiting the translation process [4]. Recently, studies have reported overexpressed miRNA-96-5p promotes gastric cancer cell proliferation [5], miR-26 affects apoptosis of hepatocellular carcinoma [6], miR-23a promotes invasion of nasopharyngeal carcinoma [7], and miR-17-5p promotes angiogenesis in nasopharyngeal carcinoma [8]. Moreover, previous studies have found that miRNAs are downregulated or overexpressed in several cancer types, including breast cancer [9], colorectal cancer [10], and HCC [11]. It has been reported that miRNA
dysregulation plays a crucial role in the metastasis of tumors [12–14]. However, the role of metastasis-related miRNA (MRMs) in HCC and its prognosis role has not been explored fully.

In this work, we examined the correlation between the expression of MRMs and the clinical data of HCC patients. A seven-MRM prognostic signature based on the training cohort was constructed for the prediction of the overall survival (OS) for HCC patients. Moreover, we constructed a nomogram to predict the OS of patients at 1, 2, and 3 years. The study provides a potential prognostic indicator for patients with HCC who have undergone surgical resection based on The Cancer Genome Atlas (TCGA) database.

2. Material and Methods

2.1. Data Acquisition. A total of 710 MRMs were retrieved from the Human Cancer Metastasis Database (https://hcmdb.i-sanger.com). The MRMs were from recurrent cases after undergoing living donor liver transplantation (LDLT). Similarly, we retrieved miRNA expression and clinical information of 375 HCC patients from the TCGA database (https://cancergenome.nih.gov). A total of 344 cases were enrolled for the study after deleting samples with no survival data or with a survival time less than 30 days.

2.2. Differentially Expressed miRNAs (DEMs). The limma package in R software was used for the analysis of differential expression of MRMs in HCC tissues and adjacent nontumor tissues. A cut-off value of \(|\log FC| > 0.5\) and FDR < 0.05 was used. Pheatmap and ggpubr packages in R software were used to generate volcano plots, heatmaps, and box plots.

2.3. Construction of Prognostic Signature. The screened clinical samples were randomly grouped into training cohort (\(n = 172\)) and validation cohort (\(n = 172\)). The clinicopathological features of the training cohort and validation cohort were recorded (Table 1). Univariate Cox regression analysis was used to identify MRMs in the training cohort which were highly correlated with HCC OS. Further, multivariate Cox regression analysis was used to filter out independent prognostic factors from this group. A survival plot of the screened miRNAs was drawn, and a prognostic signature was established using the metastasis-associated prediction formula. The risk score of each patient was calculated based on the prognostic signature constructed from the training cohort. Patients in the training cohort were divided into a high-risk group and low-risk group based on the median risk score. The Kaplan–Meier (K–M) methods were used for survival analysis of the high-risk and low-risk groups. Subsequently, the role of the prediction signature was evaluated by calculating the area under the curve (AUC) using the receiver operator characteristic (ROC) curve.

2.4. Validation of the Prognostic Signature. Patients in the validation cohort were grouped into high-risk and low-risk groups based on the median risk score of the training cohort. The risk score and formula of the validation cohort were evaluated. Further, we evaluated the OS of the high- and low-risk groups. In addition, the prognostic value of the predictive signature was evaluated using the ROC curve.

2.5. GO and KEGG Pathway Enrichment Analysis. To investigate significantly enriched functions and important pathways in which MRMs play a role, we performed Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis and the results were visualized via R software. Corrected \(P\) value < 0.05 was considered statistically significant.

2.6. PPI Network Analysis. Protein-protein interaction (PPI) network analysis data analyzed from STRING online website (https://string-db.org/). Further analysis and visualization of protein interaction network data were completed by Cytoscape software (version 3.7.2).

2.7. Nomogram Model Construction. We combined the risk score and the corresponding clinical variables (age, TNM stage, grade) to construct a nomogram for the prediction of the OS of patients at 1, 2, and 3 years. The nomogram was used for effective use and visualization of the prognostic signature.

2.8. Statistical Analysis. All gene expression data were normalized by log2 transformation. We used R software (version 3.6.2) to perform all statistical analyses. In all analyses, \(P\) value < 0.05 was considered statistically significant.

3. Result

3.1. Differentially Expressed MRMs. Among the 710 metastasis-associated genes, 335 differentially expressed MRMs were identified in the analysis of HCC and normal tissue. Volcano plots were used to visualize expression patterns of differentially expressed MRMs between HCC and nontumor tissues (Figure 1(a)). Further, a heat map and box plot were constructed using the top 10 upregulated miRNA and the top 10 downregulated miRNA (Figures 1(b) and 1(c)).

3.2. Construction of Prognostic Signature. Only 26 of the 335 MRMs were linked to the prognosis of HCC patients using univariate Cox regression analysis. Further, we performed multivariate analysis on the 26 MRMs. As a result, miR-140-3p, miR-9-5p, miR-942-5p, miR-324-3p, miR-29c-5p, miR-551a, and miR-149-5p were picked out as potential independent prognostic predictors in HCC. In addition, we validated the prognostic significance of the genes using a survival curve. High expression levels of miR-9-5p, miR-942-5p, miR-324-3p, miR-551a, and miR-149-5p were significantly correlated with poor OS. On the other hand, upregulation of miR-140-3p and miR-29c-5p indicated better survival of HCC patients (Figures 2(a)–2(g)).

Multivariate Cox regression analysis results are shown in Table 2. The prognostic signature was constructed using Cox

The study provides a potential prognostic indicator for patients with HCC who have undergone surgical resection based on The Cancer Genome Atlas (TCGA) database.
regression analysis results. The risk score for each sample was calculated using the following formula: risk score = (0.36809 \times \text{the expression of miR-942-5p}) + (0.27523 \times \text{the expression of miR-324-3p}) + (0.26632 \times \text{the expression of miR-551a}) + (0.26487 \times \text{the expression of miR-29c-5p}) + (0.10317 \times \text{the expression of miR-9-5p}) - (0.26632 \times \text{the expression of miR-29c-5p}) - (0.66679 \times \text{the expression of miR-140-3p}).

Further, we grouped the training cohort into a high-risk group (n = 86) and low-risk group (n = 86) using the median value of the risk score. The two groups were analyzed to identify the key role of the prognostic signature in predicting the prognosis of HCC. Survival analysis showed significantly low survival of samples with a high-risk score compared with samples with a low-risk score (Figure 3(a)). As shown in (Figure 3(b)), the ROC curve showed that the risk score had a significant prognostic value in HCC patients (AUC = 0.780). And the area under the curve was larger than other clinicopathological characteristics, such as AFP, pathology grade, and clinical stage. The heatmap showed the expression pattern of these seven prognostic miRNAs (Figure 3(c)), and the samples were ranked in ascending order of the parameters (Figure 3(d)).

The risk score ordered the scatterplot of patient survival status (Figure 3(e)).

### 3.3. Validation of the Prognostic Signature

Further, the cut-off value used for the training cohort was used to group the validation cohort into a high-risk group (n = 86) and a low-risk group (n = 84). Results obtained from the analysis of the validation cohort were similar to the training cohort results. The prognosis of the sample with a high-risk score significantly poor compared to the samples with low-risk score (Figure 4(a)). In addition, the ROC curve (Figure 4(b))

### Table 1: Clinicopathological characteristics of training cohort and validation cohort.

|                      | Overall | Training cohort | Validation cohort |
|----------------------|---------|-----------------|-------------------|
| n                    | 344     | 172             | 172               |
| Age (mean (SD))      | 59.35 (13.19) | 60.21 (13.30) | 58.50 (13.07)     |
| Gender = male (%)    | 236 (68.6) | 118 (68.6)     | 118 (68.6)        |
| Pathology grade (%)  |         |                 |                   |
| G1                   | 53 (15.4) | 25 (14.5)       | 28 (16.3)         |
| G2                   | 160 (46.5) | 83 (48.3)      | 77 (44.8)         |
| G3                   | 114 (33.1) | 52 (30.2)      | 62 (36.0)         |
| G4                   | 13 (3.8)  | 4 (2.5)         |                   |
| Unknown              | 4 (1.2)  | 3 (1.7)         | 1 (0.6)           |
| Clinical stage (%)   |         |                 |                   |
| Stage I              | 162 (47.1) | 74 (43.0)      | 88 (51.2)         |
| Stage II             | 77 (22.4) | 42 (24.4)      | 35 (20.3)         |
| Stage III            | 3 (0.9)  | 2 (1.2)         | 1 (0.6)           |
| Stage IIIA           | 59 (17.2) | 30 (17.4)      | 29 (16.9)         |
| Stage IIIB           | 9 (2.6)  | 4 (2.3)         | 5 (2.9)           |
| Stage IIIC           | 9 (2.6)  | 4 (2.3)         | 5 (2.9)           |
| Stage IV             | 1 (0.3)  | 0 (0.0)         | 1 (0.6)           |
| Stage IVB            | 2 (0.6)  | 1 (0.6)         |                   |
| Unknown              | 22 (6.4) | 14 (8.1)        | 8 (4.7)           |
| T classification (%) |         |                 |                   |
| T1                   | 169 (49.1) | 80 (46.5)      | 89 (51.7)         |
| T2                   | 82 (23.8) | 45 (26.2)       | 37 (21.5)         |
| T2a                  | 1 (0.3)  | 0 (0.0)         | 1 (0.6)           |
| T2b                  | 1 (0.3)  | 0 (0.0)         | 1 (0.6)           |
| T3                   | 42 (12.2) | 23 (13.4)       | 19 (11.0)         |
| T3a                  | 26 (7.6)  | 12 (7.0)        | 14 (8.1)          |
| T3b                  | 7 (2.0)  | 2 (1.2)         | 5 (2.9)           |
| T4                   | 13 (3.8) | 8 (4.7)         | 5 (2.9)           |
| TX                   | 1 (0.3)  | 1 (0.6)         | 0 (0.0)           |
| Unknown              | 2 (0.6)  | 1 (0.6)         | 1 (0.6)           |
| M classification (%) |         |                 |                   |
| M0                   | 248 (72.1) | 119 (69.2)    | 129 (75.0)        |
| M1                   | 3 (0.9)  | 2 (1.2)         | 1 (0.6)           |
| MX                   | 93 (27.0) | 51 (29.7)      | 42 (24.4)         |
| N classification (%) |         |                 |                   |
| N0                   | 241 (70.1) | 115 (66.9)    | 126 (73.3)        |
| N1                   | 3 (0.9)  | 1 (0.6)         | 2 (1.2)           |
| NX                   | 99 (28.8) | 55 (32.0)      | 44 (25.6)         |
| Unknown              | 1 (0.3)  | 1 (0.6)         | 0 (0.0)           |
showed that the risk score was effective for the prognosis of HCC patients (AUC = 0.724). Similarly, the area under the curve was larger than other clinicopathological characteristics, such as AFP, pathology grade, and clinical stage. The risk score for the validation cohort was calculated as described in the training cohort. The distribution of prognostic miRNAs between both groups was presented as a heatmap (Figure 4(c)). The distribution of risk score, the OS, and OS status were as shown (Figures 4(d) and 4(e)).

3.4. GO and KEGG Pathway Enrichment Analysis. We used three databases (TargetScan (http://www.targetscan.org/) [15], miRDB (http://www.mirdb.org/) [16], miRTarBase
Survival curve ($p = 2.608 \times 10^{-2}$)

Survival curve ($p = 1.763 \times 10^{-6}$)

Survival curve ($p = 3.81 \times 10^{-2}$)

Survival curve ($p = 2.281 \times 10^{-3}$)

Survival curve ($p = 4.342 \times 10^{-2}$)

Survival curve ($p = 1.621 \times 10^{-2}$)
Figure 2: Survival analysis for each prognostic MRM by the Kaplan–Meier plots. (a) miR-140-3p, (b) miR-149-5p, (c) miR-29c-5p, (d) miR-324-3p, (e) miR-551a, (f) miR-942-5p, and (g) miR-9-5p.

Table 2: Results of multivariate Cox regression analysis for MRMS in the training cohort.

| MRMs         | Coefficient | HR      | HR. 95L | HR. 95H | P value |
|--------------|-------------|---------|---------|---------|---------|
| hsa-miR-942-5p | 0.36809     | 1.44497 | 1.09978 | 1.89851 | 0.00822 |
| hsa-miR-324-3p | 0.27523     | 1.31683 | 0.92256 | 1.87961 | 0.12953 |
| hsa-miR-551a  | 0.26632     | 1.30516 | 1.04248 | 1.63402 | 0.02019 |
| hsa-miR-149-5p | 0.20294     | 1.22500 | 1.02264 | 1.64739 | 0.02760 |
| hsa-miR-9-5p  | 0.10317     | 1.10868 | 0.99782 | 1.23186 | 0.05494 |
| hsa-miR-29c-5p | -0.26487    | 0.76730 | 0.56868 | 1.03531 | 0.08311 |
| hsa-miR-140-3p | -0.66679    | 0.51335 | 0.32004 | 0.82342 | 0.00568 |

Figure 3: Continued.
We selected the common target genes in these three databases. However, the target genes of miR-551a and miR-29c-5p were selected based on two datasets because there are too few common target genes in the other dataset. A total of 260 target genes were used for subsequent analysis. We performed GO enrichment and KEGG pathway enrichment analyses to identify biological functions and pathways where the identified genes are implicated. GO and KEGG enrichment analysis results were as shown in Figures 5(a) and 5(b). KEGG pathway analysis showed that target genes regulated several biological pathways, including FoxO signaling pathway, cellular senescence, and miRNAs in cancer. GO enrichment analysis showed that target genes are mainly involved in response to oxygen levels, decreased oxygen level, and hypoxia at the biological process level. Neuronal cell body, nuclear chromatin, and PcG protein complex were the most enriched cellular components. Molecular function, DNA-binding transcription activator/repressor activity and RNA polymerase II-specific, and histone deacetylase binding were significantly enriched in HCC samples compared with normal cells.

3.5. PPI Network Analysis. We used the STRING online website to analyze the potential interactions between the 260 target genes of the 7 prognostic miRNAs, and the minimum
Survival probability
Validation cohort
Risk
High risk
Low risk

\( p = 2.05 \times 10^{-2} \)

(a)

ROC curve

(b)

Pathology grade (AUC = 0.497)
Clinical stage (AUC = 0.710)

(c)

Figure 4: Continued.
required interaction score was set at 0.9 (Figure 6(a)). Also, the above results were further analyzed and visualized by Cytoscape software. The top 6 nodes with greater degrees were displayed in the middle of the image, including RNF2, ESTR1, RAB5C, AGO1, CREBBP, and SUZ12 (Figure 6(b)).

3.6. Nomogram Model Construction. Moreover, we verified the effectiveness of the prognostic signature in predicting the prognosis of HCC patients using univariate Cox analysis and multivariate Cox analysis for the training cohort (Figures 7(a) and 7(b)). The results showed that the prognostic signature was an independent prognostic factor for HCC. Further, we constructed a nomogram to establish a more sensitive prediction signature to predict the prognosis of HCC (Figure 7(c)). The prognostic signature, age, sex, tumor grade, and TNM stage were incorporated into the nomogram model. The total score of the nomogram can be used for the prediction of the 1-, 2-, and 3-year OS of patients with HCC.

3.7. The Relationship between MRMs and Clinical Variables. Analysis of the correlation between clinical variables and seven MRMs showed that the risk score of elderly patients (age >65 years old) was lower compared with that of young patients (age ≤65 years old). Furthermore, the risk score of patients with advanced tumors (stages III ~IV or T3~T4) was higher than that of patients with early-stage tumors (Figures 8(a)–8(c)). miR-29c-5p was significantly correlated to T stage, grade, and stage; miR-140-3p was significantly correlated to T stage, age, gender, and stage whereas miR-149-5p was significantly correlated to T stage and age (Figures 8(d)–8(i)).

4. Discussion

HCC is one of the most lethal cancers worldwide [18]. Hepatitis-cirrhosis-HCC is the main cause of most liver cancer cases. Most patients with HCC have a history of hepatitis B or C infection [19]. Surgical resection is still the mainstream treatment approach for HCC; however, the postoperative survival of HCC patients is low due to the high incidence of metastasis [20]. Previous studies report that miRNA dysregulation is associated with metastasis of liver cancer [21–23]. However, the prognostic value of metastasis-related miRNAs in HCC has not been fully elucidated. Therefore, the identification of miRNAs and the targets associated with HCC metastasis may provide promising therapeutic avenues.

In this study, we retrieved miRNA expression profiles and clinical information of 373 HCC samples and 50 normal samples from the TCGA database. Further, we selected and analyzed differentially expressed MRMs in HCC. We identified seven MRMs (miR-140-3p, miR-9-5p, miR-942-5p, miR-324-3p, miR-29c-5p, miR-551a, and miR-149-5p) as potential independent prognostic predictors for HCC.
through univariate and multivariate analyses. Further, a prediction signature based on the 7 MRMs showed good performance in predicting the OS of HCC. GO and KEGG enrichment analysis indicated that the seven MRMs may be involved in metastasis of HCC through the regulation of different pathways. We constructed a more sensitive predictionsignature using thenomogram method to predict the prognosis of HCC.

Our results suggest that the screened MRMs are independent prognostic predictors. Out of the differentially expressed miRNAs, miR-140-3p, miR-9-5p, miR-324-3p, and miR-149-5p were implicated in HCC metastasis. On the other hand, miR-942-5p, miR-29c-5p, and miR-551 were reported in other cancer types but not in HCC. For instance, high expression levels of miR-140-3p inhibit EMT, invasion, and metastasis of HCC by targeting GRN [24], whereas miR-9-5p and miR-149-5p promote HCC progression [25, 26]. On the contrary, upregulation of miR-551a by dimethoxy curcumin hinders metastasis of ovarian cancer cells [27]. miR-135b-5p modulates APC gene in both diffuse and intestinal gastric cancer subtypes [28]. GO enrichment analysis of seven-MRMs were associated with changes in oxygen levels in biological processes. Notably, hypoxia is associated with metastasis of HCC [29, 30]. The FoxO signaling pathway was identified as the significantly enriched pathway through KEGG analysis. FoxO is reported to play a vital role in the metastasis of HCC [31]. PPI analysis revealed those seven miRNAs’ target genes with the strongest protein interactions. Moreover, it has been reported that the abnormal expression of RNF2, AGO1, CREBBP, and SUZ12 is closely related to the invasion and metastasis of HCC [32–35]. These results indicate that MRMs are associated with metastasis of HCC. However, this study has

![Figure 5: GO and KEGG pathway enrichment analysis. (a) Bar plot for signaling pathways in which MRMs play a role in KRGG. (b) GO analysis on the association of BP, CC, and MF with MRMs (BP: biological process, CC: cell component, and MF: molecular function).](image)
Figure 6: PPI network analysis. (a) PPI networks among the target genes of 7 prognostic miRNAs. (b) Core target genes of the protein interaction network.

Figure 7: Validation of the prognostic signature. (a) Univariate Cox regression analysis of risk score (RS) in HCC training cohort. (b) Multivariate Cox regression analysis of risk score in HCC training cohort. (c) Nomogram prediction model established using risk signature and clinical and pathological parameters.
a few shortcomings. We only validated the seven miRNAs prognostic signature in the validation cohort; therefore, large independent studies are needed to verify the effectiveness of this signature. In addition, we selected MRMs related to the overall survival of HCC patients and did not do further experiments to explore their mechanism in metastasis.

In conclusion, our study evaluated expression profiles of metastasis-related miRNAs retrieved from the TCGA database and established a prediction signature. The seven-miRNA molecular signature accurately predicts the prognosis of HCC; therefore, it has important implications in clinical practice.

Data Availability
The data are available at the Human Cancer Metastasis Database (https://hcmdb.i-sanger.com), TCGA database (https://cancergenome.nih.gov), TargetScan (http://www.targetscan.org/), miRDB (http://www.mirdb.org/), and miRTarBase (http://mirtarbase.mbc.nctu.edu.tw/).

Conflicts of Interest
All authors declare no conflicts of interest.
Authors’ Contributions
Yuan Chen and Guifu Wang contributed equally. Yuan Chen conceived and designed the experiment, collected experimental data, reviewed the manuscript, and finally approved the manuscript. Guifu Wang collected and analyzed the experimental data and wrote the first manuscript draft. Hao Xu carried out the analysis using R software and reviewed the manuscript. Hao Wang and Dousheng Bai reviewed the manuscript.

Acknowledgments
This work was supported by the National Natural Science Foundation of China under Grant no. 81871909; “13th Five-Year Plan” Science and Education Strong Health Project Leading Personnel of Yangzhou under Grant no. YZCXTD201801; and Provincial-Level Discipline Leader of the NJPH under Grant no. DTRC201809.

References
[1] R.-M. Chang, S. Xiao, X. Lei, H. Yang, F. Fang, and L.-Y. Yang, “miRNA-487a promotes proliferation and metastasis in hepatocellular carcinoma,” Clinical Cancer Research, vol. 23, no. 10, pp. 2593–2604, 2017.
[2] G. Sapisochin and J. Bruix, “Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches,” Nature Reviews Gastroenterology & Hepatology, vol. 14, no. 4, pp. 203–217, 2017.
[3] X. Ma, J. Gu, K. Wang et al., “Identification of a molecular subtyping system associated with the prognosis of Asian hepatocellular carcinoma patients receiving liver resection,” Scientific Reports, vol. 9, no. 1, p. 7073, 2019.
[4] S. Kuersten and E. B. Goodwin, “The power of the 3′ UTR: translational control and development,” Nature Reviews Genetics, vol. 4, no. 8, pp. 626–637, 2003.
[5] X. He and K. Zou, “MiRNA-96-5p contributed to the proliferation of gastric cancer cells by targeting FOXO3,” The Journal of Biochemistry, vol. 167, no. 1, pp. 101–108, 2020.
[6] F. F. Jin, Y. B. Wang, M. Z. Li et al., “MiR-26 enhances chemosensitivity and promotes apoptosis of hepatocellular carcinoma cells through inhibiting autophagy,” Cell Death & Disease, vol. 8, no. 1, 2017.
[7] K. Yachi, M. Tsuda, S. Kohsaka et al., “miR-23a promotes invasion of glioblastoma via HOXD10-regulated glial-mesenchymal transition,” Signal Transduction and Targeted Therapy, vol. 3, no. 1, p. 33, 2018.
[8] B. Duan, S. Shi, H. Yue et al., “Exosomal miR-17-5p promotes angiogenesis in nasopharyngeal carcinoma via targeting BAMBI,” Journal of Cancer, vol. 10, no. 26, pp. 6681–6692, 2019.
[9] A. McGuire, J. A. L. Brown, and M. J. Kerin, “Metastatic breast cancer: the potential of miRNA for diagnosis and treatment monitoring,” Cancer & Metastasis Reviews, vol. 34, no. 1, pp. 145–155, 2015.
[10] J. Dong, J. W. Tai, and L.-F. Lu, “miRNA-microbiota interaction in gut homeostasis and colorectal cancer,” Trends in Cancer, vol. 5, no. 11, pp. 666–669, 2019.
[11] Y. C. Shyu, T. L. Lee, M. J. Lu et al., “miR-122-mediated translational repression of PEG10 and its suppression in human hepatocellular carcinoma,” Journal of Translational Medicine, vol. 14, no. 1, p. 200, 2016.
[12] S. Baranwal and S. K. Alahari, “miRNA control of tumor cell invasion and metastasis,” International Journal of Cancer, vol. 126, no. 6, pp. 1283–1290, 2010.
[13] S. Torres, I. Garcia-Palmero, R. A. Bartolomé et al., “Combined miRNA profiling and proteomics demonstrates that different miRNAs target a common set of proteins to promote colorectal cancer metastasis,” The Journal of Pathology, vol. 242, no. 1, pp. 39–51, 2017.
[14] T. Wang, H. Xu, M. Qi, S. Yan, and X. Tian, “miRNA dysregulation and the risk of metastasis and invasion in papillary thyroid cancer: a systematic review and meta-analysis,” OncoTarget, vol. 9, no. 4, pp. 5473–5479, 2018.
[15] B. P. Lewis, C. B. Burge, and D. P. Bartel, “Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets,” Cell, vol. 120, no. 1, pp. 15–20, 2005.
[16] N. Wong and X. Wang, “miRDB: an online resource for microRNA target prediction and functional annotations,” Nucleic Acids Research, vol. 43, no. D1, pp. D146–D152, 2015.
[17] S.-D. Hsu, Y.-T. Tseng, S. Shrestha et al., “miTarBase update 2014: an information resource for experimentally validated miRNA-target interactions,” Nucleic Acids Research, vol. 42, no. D1, pp. D78–D85, 2014.
[18] A. Budny, P. Kozlowski, M. Kaminska et al., “[Epidermiology and risk factors of hepatocellular carcinoma],” Polski Merkuriusz Lekarski, vol. 43, no. 255, pp. 133–139, 2017.
[19] Y. A. Ghouri, I. Mian, and J. H. Rowe, “Review of hepatocellular carcinoma: epidemiology, etiology, and carcinogenesis,” Journal of Carcinogenesis, vol. 16, p. 1, 2017.
[20] S. T. Orcutt and D. A. Anaya, “Liver resection and surgical strategies for management of primary liver cancer,” Cancer Control, vol. 25, no. 1, Article ID 1073274817744621, 2018.
[21] H.-C. Zhou, J.-H. Fang, L.-R. Shang et al., “MicroRNAs miR-125b and miR-100 suppress metastasis of hepatocellular carcinoma by disrupting the formation of vessels that encapsulate tumour clusters,” The Journal of Pathology, vol. 240, no. 4, pp. 450–460, 2016.
[22] Z. Liu, W. Li, Y. Pang et al., “SF3B4 is regulated by microRNA-133b and promotes cell proliferation and metastasis in hepatocellular carcinoma,” Ebiomedicine, vol. 38, pp. 57–68, 2018.
[23] Y. Chen, Y. Guo, Y. Li et al., “miR300 regulates tumor proliferation and metastasis by targeting lymphoid enhancer-binding factor 1 in hepatocellular carcinoma,” International Journal of Oncology, vol. 54, no. 4, pp. 1282–1294, 2019.
[24] Q. Y. Zhang, C. J. Men, and X. W. Ding, “Upregulation of microRNA-140-3p inhibits epithelial-mesenchymal transition, invasion, and metastasis of hepatocellular carcinoma through inactivation of the MAPK signaling pathway by targeting GRN,” Journal of Cellular Biochemistry, vol. 120, no. 9, pp. 14885–14898, 2019.
[25] X. Dong, F. Wang, Y. Xue et al., “MicroRNA95p down-regulates KLH4 and influences the progression of hepatocellular carcinoma via the AKT signaling pathway,” International Journal of Molecular Medicine, vol. 43, no. 3, pp. 1417–1429, 2019.
[26] G. Liu, L. Yin, X. Ouyang, K. Zeng, Y. Xiao, and Y. Li, “M2 macrophages promote HCC cells invasion and migration via miR-149-5p/MMP9 signaling,” Journal of Cancer, vol. 11, no. 5, pp. 1277–1287, 2020.
[27] Z. Du and X. Sha, “Demethoxycurcumin inhibited human epithelia ovarian cancer cells’ growth via up-regulating miR-551a,” Tumour Biology, vol. 39, no. 3, Article ID 1010428317694302, 2017.
[28] L. Magalhaes, L. G. Quintana, D. C. F. Lopes et al., “APC gene is modulated by hsa-miR-135b-5p in both diffuse and intestinal gastric cancer subtypes,” *BMC Cancer*, vol. 18, no. 1, 1055 pages, 2018.

[29] C. Legendre, T. Hori, P. Loyer et al., “Drug-metabolising enzymes are down-regulated by hypoxia in differentiated human hepatoma HepaRG cells: HIF-1α involvement in CYP3A4 repression,” *European Journal of Cancer*, vol. 45, no. 16, pp. 2882–2892, 2009.

[30] Z. Liu, Y. Wang, C. Dou et al., “Hypoxia-induced up-regulation of VASP promotes invasiveness and metastasis of hepatocellular carcinoma,” *Theranostics*, vol. 8, no. 17, pp. 4649–4663, 2018.

[31] Y. Q. Hou, Y. Yao, Y. L. Bao et al., “Juglanthraquinone C induces intracellular ROS increase and apoptosis by activating the Akt/Foxo signal pathway in HCC cells,” *Oxidative Medicine and Cellular Longevity*, vol. 2016, Article ID 4941623, 18 pages, 2016.

[32] C. Qu and Y. Qu, “Down-regulation of salt-inducible kinase 1 (SIK1) is mediated by RNF2 in hepatocarcinogenesis,” *Oncotarget*, vol. 8, no. 2, pp. 3144–3155, 2017.

[33] M. Wang, L. Zhang, Z. Liu et al., “AGO1 may influence the prognosis of hepatocellular carcinoma through TGF-β pathway,” *Cell Death & Disease*, vol. 9, no. 3, p. 324, 2018.

[34] D. Y. Wen, P. Lin, H. W. Liang et al., “Up-regulation of CTD-2547G23.4 in hepatocellular carcinoma tissues and its prospective molecular regulatory mechanism: a novel qRT-PCR and bioinformatics analysis study,” *Cancer Cell International*, vol. 18, p. 74, 2018.

[35] C. Xue, K. Wang, X. Jiang et al., “The down-regulation of SUZ12 accelerates the migration and invasion of liver cancer cells via activating ERK1/2 pathway,” *Journal of Cancer*, vol. 10, no. 6, pp. 1375–1384, 2019.